One of the major constraints on the therapeutic use of oligonucleotides is inefficient delivery to their sites of action in the cytosol or nucleus. Recently it has become evident that the pathways of cellular uptake and intracellular trafficking of oligonucleotides can strongly influence their pharmacological actions. Here we provide background information on the basic processes of endocytosis and trafficking and then review recent literature on targeted delivery and subcellular trafficking of oligonucleotides in that context. A variety of approaches including molecular scale ligand-oligonucleotide conjugates, ligand-targeted nanocarriers, and the use of small molecules to enhance oligonucleotide effects are discussed
Short DNA or RNA oligonucleotides have tremendous potential as therapeutic agents. Because of their ...
Oligonucleotides are promising drug candidates due to the exceptionally high specificity they exhibi...
A continuing problem in the area of oligonucleotide-based therapeutics is the poor access of these m...
One of the major constraints on the therapeutic use of oligonucleotides is inefficient delivery to t...
Oligonucleotides manifest much promise as potential therapeutic agents. However, understanding of ho...
Significant progress is being made concerning the development of oligonucleotides as therapeutic age...
The problem of targeted delivery of antisense and siRNA oligonucleotides can be resolved into two di...
The oligonucleotide therapeutics field has seen remarkable progress over the last few years with the...
The potential use of antisense and siRNA oligonucleotides as therapeutic agents has elicited a great...
There is mounting interest in developing antisense and siRNA oligonucleotides into therapeutic entit...
The therapeutic use of antisense and siRNA oligonucleotides has been constrained by the limited abil...
We demonstrate that the biological effect of an oligonucleotide is influenced by its route of cellul...
Gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptor superfamily, h...
Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the list o...
AbstractPharmacokinetic properties of oligonucleotides are largely driven by chemistry of the backbo...
Short DNA or RNA oligonucleotides have tremendous potential as therapeutic agents. Because of their ...
Oligonucleotides are promising drug candidates due to the exceptionally high specificity they exhibi...
A continuing problem in the area of oligonucleotide-based therapeutics is the poor access of these m...
One of the major constraints on the therapeutic use of oligonucleotides is inefficient delivery to t...
Oligonucleotides manifest much promise as potential therapeutic agents. However, understanding of ho...
Significant progress is being made concerning the development of oligonucleotides as therapeutic age...
The problem of targeted delivery of antisense and siRNA oligonucleotides can be resolved into two di...
The oligonucleotide therapeutics field has seen remarkable progress over the last few years with the...
The potential use of antisense and siRNA oligonucleotides as therapeutic agents has elicited a great...
There is mounting interest in developing antisense and siRNA oligonucleotides into therapeutic entit...
The therapeutic use of antisense and siRNA oligonucleotides has been constrained by the limited abil...
We demonstrate that the biological effect of an oligonucleotide is influenced by its route of cellul...
Gastrin-releasing peptide receptor (GRPR), a member of the G protein-coupled receptor superfamily, h...
Oligonucleotides (ONs) comprise a rapidly growing class of therapeutics. In recent years, the list o...
AbstractPharmacokinetic properties of oligonucleotides are largely driven by chemistry of the backbo...
Short DNA or RNA oligonucleotides have tremendous potential as therapeutic agents. Because of their ...
Oligonucleotides are promising drug candidates due to the exceptionally high specificity they exhibi...
A continuing problem in the area of oligonucleotide-based therapeutics is the poor access of these m...